Boston KPro implants appear unsafe for children

boston-kpro-implants-appear-unsafe-for-children.jpg

FEB 08, 2018

Cornea/External Disease, Pediatric Ophth/Strabismus


Researchers examined visual outcomes and complications of Boston type 1 keratoprosthesis (KPro) implants in a pediatric population.  

Study design 

This retrospective case series included 11 eyes of 11 patients aged 16 years or younger. All patients underwent KPro surgery at 1 of 3 tertiary ophthalmology centers in Canada between 2010 to 2014.   

Before surgery, BCVA ranged from 20/600 to light perception. All 6 patients with concurrent glaucoma received a glaucoma drainage device (GDD) prior to KPro implantation. 

Outcomes 

At the last follow-up (mean 41.8 months; range 6.5 to 85.0 months), 2 eyes retained their preoperative BCVA, and 5 eyes lost light perception. The initial KPro device was retained in only 4 eyes (36.4%). 

The authors observed a high incidence of serious postoperative complications, which included retroprosthetic membrane (9 eyes), corneal melt (5 eyes) retinal detachment (5 eyes), infectious keratitis (3 eyes), endophthalmitis (3 eyes), and GDD erosion (2 eyes).  

Limitations 

This study is limited by its retrospective design and small cohort. Investigators did not address an age when KPro surgery will result in clinical outcomes similar to what has been observed in adults. 

Clinical significance 

Due to the high complication rate, the authors do not recommend KPro implantation in children. All 3 centers involved in this study have stopped offering KPro surgery for children with corneal opacification. 

The findings show that KPro surgery in children is a major undertaking, and can often lead to permanent and irreversible vision loss. Because the distance between the lens and cornea is short in children, the procedure routinely requires lensectomy and anterior vitrectomy and may warrant subtotal iridectomy and GDDs. Therefore, KPro implantation could subject children to lifelong follow-up, long-term use of topical antibiotics, and perpetual risk of sight-threatening complications. 

 

View Abstract Ophthalmology, February 2018

https://www.aao.org/editors-choice/boston-kpro-implants-appear-unsafe-children

Comments

Post a Comment

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial.  The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
Read more

Vision Improvements Reported in ProQR’s Clinical Trial for LCA10 Treatment

Image
ProQR, a biotech company in the Netherlands, ha s reported vision improvements for patients in a  Phase 1/2 clinical trial for QR-110 , a therapy for people with  Leber congenital amaurosis  10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world. The company reported that 60 percent of su bjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course . The treatment was also safe for patients. As a result of the encouraging interim results, ProQR has concluded the Phase 1/2 trial and plans to move the treatment into a Phase 2/3 clinical trial. Ten people were treated in the Phase 1/2 study. Results from the interim analy sis were presented on September 5, 2018, at the Retinal Degeneration 2018 meeting in Killarney,   Ireland , by principal investigator   Artur Cideciyan , PhD , research professor of ophthalmology at the   Scheie Eye Ins...
Read more

Cataract Surgery Leads to Longer Life in Women

Image
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
Read more